Calidi Biotherapeutics, Inc.

Item 1.01 Entry into a Material Definitive Agreement. On September 17, 2026, Calidi Biotherapeutics, Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with certain accredited investors and/or qualified institutional buyers named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell directly to the Purchasers, in a registered direct offering (the “Offering”), an aggregate of 1,025,640 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $1.17 per Share. The Offering closed on September 21, 2026. The gross proceeds to the Company from the Offering were approximately $1.2 million, before deducting estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. The Company did not engage an underwriter, placement agent, broker-dealer or other agent in connection with the Offering, and no underwriting discounts or commissions, placement agent fees or similar compensation were paid in connection with the sale of the Shares. The Shares were offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-282456) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on October 10, 2024, the base prospectus included therein and the prospectus supplement dated September 17, 2026, filed with the SEC. The Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers. Pursuant to the terms of the Purchase Agreement, and subject to certain exceptions as set forth therein, the Company agreed that, for a period of 45 days following the closing of the Offering, it will not issue, offer, sell or otherwise dispose of, or announce the issuance, offer, sale or other disposition of, any equity securities or equity-linked or related securities without the prior written consent of Purchasers holding more than 50% in interest of the Shares purchased under the Purchase Agreement. In connection with the Offering, the Company’s directors and executive officers entered into lock-up agreements pursuant to which, subject to customary exceptions, they agreed not to offer, sell, contract to sell, pledge or otherwise transfer or dispose of any shares of Common Stock or securities convertible into, exercisable for or exchangeable for Common Stock for a period of 60 days following the closing of the Offering. The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Purchase Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K (“Form 8-K”) and is incorporated herein by reference. The legal opinion of Sichenzia Ross Ference Carmel LLP relating to the validity of the securities issued in the Transactions is filed herewith as Exhibit 5.1. This Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item 8.01 Other Events. On September 17, 2026, the Company issued a press release announcing the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K, and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ───────────────────────────────────────────────────────────────────────────────────────── 5.1 Opinion of Sichenzia Ross Ference Carmel LLP. 10.1 Form of the Securities Purchase Agreement. 23.1 Consent of Sichenzia Ross Ference Carmel, LLP (contained in Exhibit 5.1) 99.1 Press Release dated September 17, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).